Drugs / LY3475070
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04148937 | Jan 2020 → May 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3475070 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04148937 ↗ |
| Action | Inhibit | “CD73 inhibitor LY3475070” NCT04148937 ↗ |
| Modality | Small molecule | — CHEMBL4792487 ↗ |
| Route | Oral | “Administered orally” NCT04148937 ↗ |